Global Long-acting Antipsychotic Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Long-acting Antipsychotic market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-acting Antipsychotic sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Antipsychotic sales for 2024 through 2030. With Long-acting Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Antipsychotic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Antipsychotic.
United States market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Long-acting Antipsychotic players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Antipsychotic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Long-acting Antipsychotic market?
What factors are driving Long-acting Antipsychotic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Antipsychotic market opportunities vary by end market size?
How does Long-acting Antipsychotic break out by Type, by Application?
The global Long-acting Antipsychotic market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-acting Antipsychotic sales in 2023, providing a comprehensive analysis by region and market sector of projected Long-acting Antipsychotic sales for 2024 through 2030. With Long-acting Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Antipsychotic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Antipsychotic.
United States market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Long-acting Antipsychotic is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Long-acting Antipsychotic players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Antipsychotic market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aripiprazole
- Haloperidol
- Paliperidone
- Risperidone
- Olanzapine
- Others
- Schizophrenia
- Bipolar Disorder
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Oakwood Labs
- Teva
- MedinCell
- Janssen
- Otsuka America Pharmaceutical, Inc.
- Lundbeck
- Eli Lilly
- Alkermes
- Par Pharmaceutical
- AbbVie
- Luye Pharmaceutical
What is the 10-year outlook for the global Long-acting Antipsychotic market?
What factors are driving Long-acting Antipsychotic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Antipsychotic market opportunities vary by end market size?
How does Long-acting Antipsychotic break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Antipsychotic Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Long-acting Antipsychotic by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Long-acting Antipsychotic by Country/Region, 2019, 2023 & 2030
2.2 Long-acting Antipsychotic Segment by Type
2.2.1 Aripiprazole
2.2.2 Haloperidol
2.2.3 Paliperidone
2.2.4 Risperidone
2.2.5 Olanzapine
2.2.6 Others
2.3 Long-acting Antipsychotic Sales by Type
2.3.1 Global Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
2.3.2 Global Long-acting Antipsychotic Revenue and Market Share by Type (2019-2024)
2.3.3 Global Long-acting Antipsychotic Sale Price by Type (2019-2024)
2.4 Long-acting Antipsychotic Segment by Application
2.4.1 Schizophrenia
2.4.2 Bipolar Disorder
2.4.3 Others
2.5 Long-acting Antipsychotic Sales by Application
2.5.1 Global Long-acting Antipsychotic Sale Market Share by Application (2019-2024)
2.5.2 Global Long-acting Antipsychotic Revenue and Market Share by Application (2019-2024)
2.5.3 Global Long-acting Antipsychotic Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Antipsychotic Breakdown Data by Company
3.1.1 Global Long-acting Antipsychotic Annual Sales by Company (2019-2024)
3.1.2 Global Long-acting Antipsychotic Sales Market Share by Company (2019-2024)
3.2 Global Long-acting Antipsychotic Annual Revenue by Company (2019-2024)
3.2.1 Global Long-acting Antipsychotic Revenue by Company (2019-2024)
3.2.2 Global Long-acting Antipsychotic Revenue Market Share by Company (2019-2024)
3.3 Global Long-acting Antipsychotic Sale Price by Company
3.4 Key Manufacturers Long-acting Antipsychotic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Antipsychotic Product Location Distribution
3.4.2 Players Long-acting Antipsychotic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING ANTIPSYCHOTIC BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Antipsychotic Market Size by Geographic Region (2019-2024)
4.1.1 Global Long-acting Antipsychotic Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Long-acting Antipsychotic Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Long-acting Antipsychotic Market Size by Country/Region (2019-2024)
4.2.1 Global Long-acting Antipsychotic Annual Sales by Country/Region (2019-2024)
4.2.2 Global Long-acting Antipsychotic Annual Revenue by Country/Region (2019-2024)
4.3 Americas Long-acting Antipsychotic Sales Growth
4.4 APAC Long-acting Antipsychotic Sales Growth
4.5 Europe Long-acting Antipsychotic Sales Growth
4.6 Middle East & Africa Long-acting Antipsychotic Sales Growth
5 AMERICAS
5.1 Americas Long-acting Antipsychotic Sales by Country
5.1.1 Americas Long-acting Antipsychotic Sales by Country (2019-2024)
5.1.2 Americas Long-acting Antipsychotic Revenue by Country (2019-2024)
5.2 Americas Long-acting Antipsychotic Sales by Type (2019-2024)
5.3 Americas Long-acting Antipsychotic Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Antipsychotic Sales by Region
6.1.1 APAC Long-acting Antipsychotic Sales by Region (2019-2024)
6.1.2 APAC Long-acting Antipsychotic Revenue by Region (2019-2024)
6.2 APAC Long-acting Antipsychotic Sales by Type (2019-2024)
6.3 APAC Long-acting Antipsychotic Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Antipsychotic by Country
7.1.1 Europe Long-acting Antipsychotic Sales by Country (2019-2024)
7.1.2 Europe Long-acting Antipsychotic Revenue by Country (2019-2024)
7.2 Europe Long-acting Antipsychotic Sales by Type (2019-2024)
7.3 Europe Long-acting Antipsychotic Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Antipsychotic by Country
8.1.1 Middle East & Africa Long-acting Antipsychotic Sales by Country (2019-2024)
8.1.2 Middle East & Africa Long-acting Antipsychotic Revenue by Country (2019-2024)
8.2 Middle East & Africa Long-acting Antipsychotic Sales by Type (2019-2024)
8.3 Middle East & Africa Long-acting Antipsychotic Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Antipsychotic
10.3 Manufacturing Process Analysis of Long-acting Antipsychotic
10.4 Industry Chain Structure of Long-acting Antipsychotic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Antipsychotic Distributors
11.3 Long-acting Antipsychotic Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING ANTIPSYCHOTIC BY GEOGRAPHIC REGION
12.1 Global Long-acting Antipsychotic Market Size Forecast by Region
12.1.1 Global Long-acting Antipsychotic Forecast by Region (2025-2030)
12.1.2 Global Long-acting Antipsychotic Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Long-acting Antipsychotic Forecast by Type (2025-2030)
12.7 Global Long-acting Antipsychotic Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Oakwood Labs
13.1.1 Oakwood Labs Company Information
13.1.2 Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications
13.1.3 Oakwood Labs Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Oakwood Labs Main Business Overview
13.1.5 Oakwood Labs Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Long-acting Antipsychotic Product Portfolios and Specifications
13.2.3 Teva Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 MedinCell
13.3.1 MedinCell Company Information
13.3.2 MedinCell Long-acting Antipsychotic Product Portfolios and Specifications
13.3.3 MedinCell Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MedinCell Main Business Overview
13.3.5 MedinCell Latest Developments
13.4 Janssen
13.4.1 Janssen Company Information
13.4.2 Janssen Long-acting Antipsychotic Product Portfolios and Specifications
13.4.3 Janssen Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Janssen Main Business Overview
13.4.5 Janssen Latest Developments
13.5 Otsuka America Pharmaceutical, Inc.
13.5.1 Otsuka America Pharmaceutical, Inc. Company Information
13.5.2 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications
13.5.3 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview
13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments
13.6 Lundbeck
13.6.1 Lundbeck Company Information
13.6.2 Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications
13.6.3 Lundbeck Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lundbeck Main Business Overview
13.6.5 Lundbeck Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications
13.7.3 Eli Lilly Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Alkermes
13.8.1 Alkermes Company Information
13.8.2 Alkermes Long-acting Antipsychotic Product Portfolios and Specifications
13.8.3 Alkermes Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Alkermes Main Business Overview
13.8.5 Alkermes Latest Developments
13.9 Par Pharmaceutical
13.9.1 Par Pharmaceutical Company Information
13.9.2 Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.9.3 Par Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Par Pharmaceutical Main Business Overview
13.9.5 Par Pharmaceutical Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Long-acting Antipsychotic Product Portfolios and Specifications
13.10.3 AbbVie Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 Luye Pharmaceutical
13.11.1 Luye Pharmaceutical Company Information
13.11.2 Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.11.3 Luye Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Luye Pharmaceutical Main Business Overview
13.11.5 Luye Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Antipsychotic Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Long-acting Antipsychotic by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Long-acting Antipsychotic by Country/Region, 2019, 2023 & 2030
2.2 Long-acting Antipsychotic Segment by Type
2.2.1 Aripiprazole
2.2.2 Haloperidol
2.2.3 Paliperidone
2.2.4 Risperidone
2.2.5 Olanzapine
2.2.6 Others
2.3 Long-acting Antipsychotic Sales by Type
2.3.1 Global Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
2.3.2 Global Long-acting Antipsychotic Revenue and Market Share by Type (2019-2024)
2.3.3 Global Long-acting Antipsychotic Sale Price by Type (2019-2024)
2.4 Long-acting Antipsychotic Segment by Application
2.4.1 Schizophrenia
2.4.2 Bipolar Disorder
2.4.3 Others
2.5 Long-acting Antipsychotic Sales by Application
2.5.1 Global Long-acting Antipsychotic Sale Market Share by Application (2019-2024)
2.5.2 Global Long-acting Antipsychotic Revenue and Market Share by Application (2019-2024)
2.5.3 Global Long-acting Antipsychotic Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Antipsychotic Breakdown Data by Company
3.1.1 Global Long-acting Antipsychotic Annual Sales by Company (2019-2024)
3.1.2 Global Long-acting Antipsychotic Sales Market Share by Company (2019-2024)
3.2 Global Long-acting Antipsychotic Annual Revenue by Company (2019-2024)
3.2.1 Global Long-acting Antipsychotic Revenue by Company (2019-2024)
3.2.2 Global Long-acting Antipsychotic Revenue Market Share by Company (2019-2024)
3.3 Global Long-acting Antipsychotic Sale Price by Company
3.4 Key Manufacturers Long-acting Antipsychotic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Antipsychotic Product Location Distribution
3.4.2 Players Long-acting Antipsychotic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING ANTIPSYCHOTIC BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Antipsychotic Market Size by Geographic Region (2019-2024)
4.1.1 Global Long-acting Antipsychotic Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Long-acting Antipsychotic Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Long-acting Antipsychotic Market Size by Country/Region (2019-2024)
4.2.1 Global Long-acting Antipsychotic Annual Sales by Country/Region (2019-2024)
4.2.2 Global Long-acting Antipsychotic Annual Revenue by Country/Region (2019-2024)
4.3 Americas Long-acting Antipsychotic Sales Growth
4.4 APAC Long-acting Antipsychotic Sales Growth
4.5 Europe Long-acting Antipsychotic Sales Growth
4.6 Middle East & Africa Long-acting Antipsychotic Sales Growth
5 AMERICAS
5.1 Americas Long-acting Antipsychotic Sales by Country
5.1.1 Americas Long-acting Antipsychotic Sales by Country (2019-2024)
5.1.2 Americas Long-acting Antipsychotic Revenue by Country (2019-2024)
5.2 Americas Long-acting Antipsychotic Sales by Type (2019-2024)
5.3 Americas Long-acting Antipsychotic Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Antipsychotic Sales by Region
6.1.1 APAC Long-acting Antipsychotic Sales by Region (2019-2024)
6.1.2 APAC Long-acting Antipsychotic Revenue by Region (2019-2024)
6.2 APAC Long-acting Antipsychotic Sales by Type (2019-2024)
6.3 APAC Long-acting Antipsychotic Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Antipsychotic by Country
7.1.1 Europe Long-acting Antipsychotic Sales by Country (2019-2024)
7.1.2 Europe Long-acting Antipsychotic Revenue by Country (2019-2024)
7.2 Europe Long-acting Antipsychotic Sales by Type (2019-2024)
7.3 Europe Long-acting Antipsychotic Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Antipsychotic by Country
8.1.1 Middle East & Africa Long-acting Antipsychotic Sales by Country (2019-2024)
8.1.2 Middle East & Africa Long-acting Antipsychotic Revenue by Country (2019-2024)
8.2 Middle East & Africa Long-acting Antipsychotic Sales by Type (2019-2024)
8.3 Middle East & Africa Long-acting Antipsychotic Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Antipsychotic
10.3 Manufacturing Process Analysis of Long-acting Antipsychotic
10.4 Industry Chain Structure of Long-acting Antipsychotic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Antipsychotic Distributors
11.3 Long-acting Antipsychotic Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING ANTIPSYCHOTIC BY GEOGRAPHIC REGION
12.1 Global Long-acting Antipsychotic Market Size Forecast by Region
12.1.1 Global Long-acting Antipsychotic Forecast by Region (2025-2030)
12.1.2 Global Long-acting Antipsychotic Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Long-acting Antipsychotic Forecast by Type (2025-2030)
12.7 Global Long-acting Antipsychotic Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Oakwood Labs
13.1.1 Oakwood Labs Company Information
13.1.2 Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications
13.1.3 Oakwood Labs Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Oakwood Labs Main Business Overview
13.1.5 Oakwood Labs Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Long-acting Antipsychotic Product Portfolios and Specifications
13.2.3 Teva Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 MedinCell
13.3.1 MedinCell Company Information
13.3.2 MedinCell Long-acting Antipsychotic Product Portfolios and Specifications
13.3.3 MedinCell Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MedinCell Main Business Overview
13.3.5 MedinCell Latest Developments
13.4 Janssen
13.4.1 Janssen Company Information
13.4.2 Janssen Long-acting Antipsychotic Product Portfolios and Specifications
13.4.3 Janssen Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Janssen Main Business Overview
13.4.5 Janssen Latest Developments
13.5 Otsuka America Pharmaceutical, Inc.
13.5.1 Otsuka America Pharmaceutical, Inc. Company Information
13.5.2 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications
13.5.3 Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview
13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments
13.6 Lundbeck
13.6.1 Lundbeck Company Information
13.6.2 Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications
13.6.3 Lundbeck Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lundbeck Main Business Overview
13.6.5 Lundbeck Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications
13.7.3 Eli Lilly Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Alkermes
13.8.1 Alkermes Company Information
13.8.2 Alkermes Long-acting Antipsychotic Product Portfolios and Specifications
13.8.3 Alkermes Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Alkermes Main Business Overview
13.8.5 Alkermes Latest Developments
13.9 Par Pharmaceutical
13.9.1 Par Pharmaceutical Company Information
13.9.2 Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.9.3 Par Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Par Pharmaceutical Main Business Overview
13.9.5 Par Pharmaceutical Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Long-acting Antipsychotic Product Portfolios and Specifications
13.10.3 AbbVie Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 Luye Pharmaceutical
13.11.1 Luye Pharmaceutical Company Information
13.11.2 Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
13.11.3 Luye Pharmaceutical Long-acting Antipsychotic Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Luye Pharmaceutical Main Business Overview
13.11.5 Luye Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-acting Antipsychotic Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Long-acting Antipsychotic Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aripiprazole
Table 4. Major Players of Haloperidol
Table 5. Major Players of Paliperidone
Table 6. Major Players of Risperidone
Table 7. Major Players of Olanzapine
Table 8. Major Players of Others
Table 9. Global Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 10. Global Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Table 11. Global Long-acting Antipsychotic Revenue by Type (2019-2024) & ($ million)
Table 12. Global Long-acting Antipsychotic Revenue Market Share by Type (2019-2024)
Table 13. Global Long-acting Antipsychotic Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Long-acting Antipsychotic Sale by Application (2019-2024) & (K Units)
Table 15. Global Long-acting Antipsychotic Sale Market Share by Application (2019-2024)
Table 16. Global Long-acting Antipsychotic Revenue by Application (2019-2024) & ($ million)
Table 17. Global Long-acting Antipsychotic Revenue Market Share by Application (2019-2024)
Table 18. Global Long-acting Antipsychotic Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Long-acting Antipsychotic Sales by Company (2019-2024) & (K Units)
Table 20. Global Long-acting Antipsychotic Sales Market Share by Company (2019-2024)
Table 21. Global Long-acting Antipsychotic Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Long-acting Antipsychotic Revenue Market Share by Company (2019-2024)
Table 23. Global Long-acting Antipsychotic Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Long-acting Antipsychotic Producing Area Distribution and Sales Area
Table 25. Players Long-acting Antipsychotic Products Offered
Table 26. Long-acting Antipsychotic Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Long-acting Antipsychotic Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Long-acting Antipsychotic Sales Market Share Geographic Region (2019-2024)
Table 31. Global Long-acting Antipsychotic Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Long-acting Antipsychotic Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Long-acting Antipsychotic Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Long-acting Antipsychotic Sales Market Share by Country/Region (2019-2024)
Table 35. Global Long-acting Antipsychotic Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Long-acting Antipsychotic Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 38. Americas Long-acting Antipsychotic Sales Market Share by Country (2019-2024)
Table 39. Americas Long-acting Antipsychotic Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 41. Americas Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 42. APAC Long-acting Antipsychotic Sales by Region (2019-2024) & (K Units)
Table 43. APAC Long-acting Antipsychotic Sales Market Share by Region (2019-2024)
Table 44. APAC Long-acting Antipsychotic Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 46. APAC Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 47. Europe Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 48. Europe Long-acting Antipsychotic Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 50. Europe Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 54. Middle East & Africa Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Long-acting Antipsychotic
Table 56. Key Market Challenges & Risks of Long-acting Antipsychotic
Table 57. Key Industry Trends of Long-acting Antipsychotic
Table 58. Long-acting Antipsychotic Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Long-acting Antipsychotic Distributors List
Table 61. Long-acting Antipsychotic Customer List
Table 62. Global Long-acting Antipsychotic Sales Forecast by Region (2025-2030) & (K Units)
Table 63. Global Long-acting Antipsychotic Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Americas Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Americas Long-acting Antipsychotic Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. APAC Long-acting Antipsychotic Sales Forecast by Region (2025-2030) & (K Units)
Table 67. APAC Long-acting Antipsychotic Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Europe Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Europe Long-acting Antipsychotic Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Middle East & Africa Long-acting Antipsychotic Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Global Long-acting Antipsychotic Sales Forecast by Type (2025-2030) & (K Units)
Table 73. Global Long-acting Antipsychotic Revenue Forecast by Type (2025-2030) & ($ millions)
Table 74. Global Long-acting Antipsychotic Sales Forecast by Application (2025-2030) & (K Units)
Table 75. Global Long-acting Antipsychotic Revenue Forecast by Application (2025-2030) & ($ millions)
Table 76. Oakwood Labs Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 77. Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications
Table 78. Oakwood Labs Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 79. Oakwood Labs Main Business
Table 80. Oakwood Labs Latest Developments
Table 81. Teva Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 82. Teva Long-acting Antipsychotic Product Portfolios and Specifications
Table 83. Teva Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Teva Main Business
Table 85. Teva Latest Developments
Table 86. MedinCell Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 87. MedinCell Long-acting Antipsychotic Product Portfolios and Specifications
Table 88. MedinCell Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. MedinCell Main Business
Table 90. MedinCell Latest Developments
Table 91. Janssen Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 92. Janssen Long-acting Antipsychotic Product Portfolios and Specifications
Table 93. Janssen Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Janssen Main Business
Table 95. Janssen Latest Developments
Table 96. Otsuka America Pharmaceutical, Inc. Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 97. Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications
Table 98. Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Otsuka America Pharmaceutical, Inc. Main Business
Table 100. Otsuka America Pharmaceutical, Inc. Latest Developments
Table 101. Lundbeck Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 102. Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications
Table 103. Lundbeck Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Lundbeck Main Business
Table 105. Lundbeck Latest Developments
Table 106. Eli Lilly Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 107. Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications
Table 108. Eli Lilly Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Eli Lilly Main Business
Table 110. Eli Lilly Latest Developments
Table 111. Alkermes Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 112. Alkermes Long-acting Antipsychotic Product Portfolios and Specifications
Table 113. Alkermes Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Alkermes Main Business
Table 115. Alkermes Latest Developments
Table 116. Par Pharmaceutical Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 117. Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
Table 118. Par Pharmaceutical Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Par Pharmaceutical Main Business
Table 120. Par Pharmaceutical Latest Developments
Table 121. AbbVie Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 122. AbbVie Long-acting Antipsychotic Product Portfolios and Specifications
Table 123. AbbVie Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Luye Pharmaceutical Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 127. Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
Table 128. Luye Pharmaceutical Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Luye Pharmaceutical Main Business
Table 130. Luye Pharmaceutical Latest Developments
Table 1. Long-acting Antipsychotic Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Long-acting Antipsychotic Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aripiprazole
Table 4. Major Players of Haloperidol
Table 5. Major Players of Paliperidone
Table 6. Major Players of Risperidone
Table 7. Major Players of Olanzapine
Table 8. Major Players of Others
Table 9. Global Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 10. Global Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Table 11. Global Long-acting Antipsychotic Revenue by Type (2019-2024) & ($ million)
Table 12. Global Long-acting Antipsychotic Revenue Market Share by Type (2019-2024)
Table 13. Global Long-acting Antipsychotic Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Long-acting Antipsychotic Sale by Application (2019-2024) & (K Units)
Table 15. Global Long-acting Antipsychotic Sale Market Share by Application (2019-2024)
Table 16. Global Long-acting Antipsychotic Revenue by Application (2019-2024) & ($ million)
Table 17. Global Long-acting Antipsychotic Revenue Market Share by Application (2019-2024)
Table 18. Global Long-acting Antipsychotic Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Long-acting Antipsychotic Sales by Company (2019-2024) & (K Units)
Table 20. Global Long-acting Antipsychotic Sales Market Share by Company (2019-2024)
Table 21. Global Long-acting Antipsychotic Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Long-acting Antipsychotic Revenue Market Share by Company (2019-2024)
Table 23. Global Long-acting Antipsychotic Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Long-acting Antipsychotic Producing Area Distribution and Sales Area
Table 25. Players Long-acting Antipsychotic Products Offered
Table 26. Long-acting Antipsychotic Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Long-acting Antipsychotic Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Long-acting Antipsychotic Sales Market Share Geographic Region (2019-2024)
Table 31. Global Long-acting Antipsychotic Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Long-acting Antipsychotic Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Long-acting Antipsychotic Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Long-acting Antipsychotic Sales Market Share by Country/Region (2019-2024)
Table 35. Global Long-acting Antipsychotic Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Long-acting Antipsychotic Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 38. Americas Long-acting Antipsychotic Sales Market Share by Country (2019-2024)
Table 39. Americas Long-acting Antipsychotic Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 41. Americas Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 42. APAC Long-acting Antipsychotic Sales by Region (2019-2024) & (K Units)
Table 43. APAC Long-acting Antipsychotic Sales Market Share by Region (2019-2024)
Table 44. APAC Long-acting Antipsychotic Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 46. APAC Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 47. Europe Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 48. Europe Long-acting Antipsychotic Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 50. Europe Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Long-acting Antipsychotic Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Long-acting Antipsychotic Sales by Type (2019-2024) & (K Units)
Table 54. Middle East & Africa Long-acting Antipsychotic Sales by Application (2019-2024) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Long-acting Antipsychotic
Table 56. Key Market Challenges & Risks of Long-acting Antipsychotic
Table 57. Key Industry Trends of Long-acting Antipsychotic
Table 58. Long-acting Antipsychotic Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Long-acting Antipsychotic Distributors List
Table 61. Long-acting Antipsychotic Customer List
Table 62. Global Long-acting Antipsychotic Sales Forecast by Region (2025-2030) & (K Units)
Table 63. Global Long-acting Antipsychotic Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Americas Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Americas Long-acting Antipsychotic Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. APAC Long-acting Antipsychotic Sales Forecast by Region (2025-2030) & (K Units)
Table 67. APAC Long-acting Antipsychotic Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Europe Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Europe Long-acting Antipsychotic Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Long-acting Antipsychotic Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Middle East & Africa Long-acting Antipsychotic Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Global Long-acting Antipsychotic Sales Forecast by Type (2025-2030) & (K Units)
Table 73. Global Long-acting Antipsychotic Revenue Forecast by Type (2025-2030) & ($ millions)
Table 74. Global Long-acting Antipsychotic Sales Forecast by Application (2025-2030) & (K Units)
Table 75. Global Long-acting Antipsychotic Revenue Forecast by Application (2025-2030) & ($ millions)
Table 76. Oakwood Labs Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 77. Oakwood Labs Long-acting Antipsychotic Product Portfolios and Specifications
Table 78. Oakwood Labs Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 79. Oakwood Labs Main Business
Table 80. Oakwood Labs Latest Developments
Table 81. Teva Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 82. Teva Long-acting Antipsychotic Product Portfolios and Specifications
Table 83. Teva Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Teva Main Business
Table 85. Teva Latest Developments
Table 86. MedinCell Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 87. MedinCell Long-acting Antipsychotic Product Portfolios and Specifications
Table 88. MedinCell Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. MedinCell Main Business
Table 90. MedinCell Latest Developments
Table 91. Janssen Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 92. Janssen Long-acting Antipsychotic Product Portfolios and Specifications
Table 93. Janssen Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Janssen Main Business
Table 95. Janssen Latest Developments
Table 96. Otsuka America Pharmaceutical, Inc. Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 97. Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Product Portfolios and Specifications
Table 98. Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Otsuka America Pharmaceutical, Inc. Main Business
Table 100. Otsuka America Pharmaceutical, Inc. Latest Developments
Table 101. Lundbeck Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 102. Lundbeck Long-acting Antipsychotic Product Portfolios and Specifications
Table 103. Lundbeck Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Lundbeck Main Business
Table 105. Lundbeck Latest Developments
Table 106. Eli Lilly Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 107. Eli Lilly Long-acting Antipsychotic Product Portfolios and Specifications
Table 108. Eli Lilly Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Eli Lilly Main Business
Table 110. Eli Lilly Latest Developments
Table 111. Alkermes Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 112. Alkermes Long-acting Antipsychotic Product Portfolios and Specifications
Table 113. Alkermes Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Alkermes Main Business
Table 115. Alkermes Latest Developments
Table 116. Par Pharmaceutical Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 117. Par Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
Table 118. Par Pharmaceutical Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Par Pharmaceutical Main Business
Table 120. Par Pharmaceutical Latest Developments
Table 121. AbbVie Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 122. AbbVie Long-acting Antipsychotic Product Portfolios and Specifications
Table 123. AbbVie Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Luye Pharmaceutical Basic Information, Long-acting Antipsychotic Manufacturing Base, Sales Area and Its Competitors
Table 127. Luye Pharmaceutical Long-acting Antipsychotic Product Portfolios and Specifications
Table 128. Luye Pharmaceutical Long-acting Antipsychotic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Luye Pharmaceutical Main Business
Table 130. Luye Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Long-acting Antipsychotic
Figure 2. Long-acting Antipsychotic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Antipsychotic Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Long-acting Antipsychotic Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Long-acting Antipsychotic Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Long-acting Antipsychotic Sales Market Share by Country/Region (2023)
Figure 10. Long-acting Antipsychotic Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aripiprazole
Figure 12. Product Picture of Haloperidol
Figure 13. Product Picture of Paliperidone
Figure 14. Product Picture of Risperidone
Figure 15. Product Picture of Olanzapine
Figure 16. Product Picture of Others
Figure 17. Global Long-acting Antipsychotic Sales Market Share by Type in 2023
Figure 18. Global Long-acting Antipsychotic Revenue Market Share by Type (2019-2024)
Figure 19. Long-acting Antipsychotic Consumed in Schizophrenia
Figure 20. Global Long-acting Antipsychotic Market: Schizophrenia (2019-2024) & (K Units)
Figure 21. Long-acting Antipsychotic Consumed in Bipolar Disorder
Figure 22. Global Long-acting Antipsychotic Market: Bipolar Disorder (2019-2024) & (K Units)
Figure 23. Long-acting Antipsychotic Consumed in Others
Figure 24. Global Long-acting Antipsychotic Market: Others (2019-2024) & (K Units)
Figure 25. Global Long-acting Antipsychotic Sale Market Share by Application (2023)
Figure 26. Global Long-acting Antipsychotic Revenue Market Share by Application in 2023
Figure 27. Long-acting Antipsychotic Sales by Company in 2023 (K Units)
Figure 28. Global Long-acting Antipsychotic Sales Market Share by Company in 2023
Figure 29. Long-acting Antipsychotic Revenue by Company in 2023 ($ millions)
Figure 30. Global Long-acting Antipsychotic Revenue Market Share by Company in 2023
Figure 31. Global Long-acting Antipsychotic Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global Long-acting Antipsychotic Revenue Market Share by Geographic Region in 2023
Figure 33. Americas Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 34. Americas Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 35. APAC Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 36. APAC Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 37. Europe Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 38. Europe Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 39. Middle East & Africa Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 40. Middle East & Africa Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 41. Americas Long-acting Antipsychotic Sales Market Share by Country in 2023
Figure 42. Americas Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Figure 43. Americas Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 44. Americas Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 45. United States Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 46. Canada Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 47. Mexico Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 48. Brazil Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 49. APAC Long-acting Antipsychotic Sales Market Share by Region in 2023
Figure 50. APAC Long-acting Antipsychotic Revenue Market Share by Region (2019-2024)
Figure 51. APAC Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 52. APAC Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 53. China Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 54. Japan Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 55. South Korea Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 56. Southeast Asia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 57. India Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 58. Australia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 59. China Taiwan Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 60. Europe Long-acting Antipsychotic Sales Market Share by Country in 2023
Figure 61. Europe Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Figure 62. Europe Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 63. Europe Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 64. Germany Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 65. France Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 66. UK Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 67. Italy Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 68. Russia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 69. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Country (2019-2024)
Figure 70. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 72. Egypt Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 73. South Africa Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 74. Israel Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 75. Turkey Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 76. GCC Countries Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Long-acting Antipsychotic in 2023
Figure 78. Manufacturing Process Analysis of Long-acting Antipsychotic
Figure 79. Industry Chain Structure of Long-acting Antipsychotic
Figure 80. Channels of Distribution
Figure 81. Global Long-acting Antipsychotic Sales Market Forecast by Region (2025-2030)
Figure 82. Global Long-acting Antipsychotic Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Long-acting Antipsychotic Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Long-acting Antipsychotic Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Long-acting Antipsychotic Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Long-acting Antipsychotic Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Long-acting Antipsychotic
Figure 2. Long-acting Antipsychotic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Antipsychotic Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Long-acting Antipsychotic Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Long-acting Antipsychotic Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Long-acting Antipsychotic Sales Market Share by Country/Region (2023)
Figure 10. Long-acting Antipsychotic Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aripiprazole
Figure 12. Product Picture of Haloperidol
Figure 13. Product Picture of Paliperidone
Figure 14. Product Picture of Risperidone
Figure 15. Product Picture of Olanzapine
Figure 16. Product Picture of Others
Figure 17. Global Long-acting Antipsychotic Sales Market Share by Type in 2023
Figure 18. Global Long-acting Antipsychotic Revenue Market Share by Type (2019-2024)
Figure 19. Long-acting Antipsychotic Consumed in Schizophrenia
Figure 20. Global Long-acting Antipsychotic Market: Schizophrenia (2019-2024) & (K Units)
Figure 21. Long-acting Antipsychotic Consumed in Bipolar Disorder
Figure 22. Global Long-acting Antipsychotic Market: Bipolar Disorder (2019-2024) & (K Units)
Figure 23. Long-acting Antipsychotic Consumed in Others
Figure 24. Global Long-acting Antipsychotic Market: Others (2019-2024) & (K Units)
Figure 25. Global Long-acting Antipsychotic Sale Market Share by Application (2023)
Figure 26. Global Long-acting Antipsychotic Revenue Market Share by Application in 2023
Figure 27. Long-acting Antipsychotic Sales by Company in 2023 (K Units)
Figure 28. Global Long-acting Antipsychotic Sales Market Share by Company in 2023
Figure 29. Long-acting Antipsychotic Revenue by Company in 2023 ($ millions)
Figure 30. Global Long-acting Antipsychotic Revenue Market Share by Company in 2023
Figure 31. Global Long-acting Antipsychotic Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global Long-acting Antipsychotic Revenue Market Share by Geographic Region in 2023
Figure 33. Americas Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 34. Americas Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 35. APAC Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 36. APAC Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 37. Europe Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 38. Europe Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 39. Middle East & Africa Long-acting Antipsychotic Sales 2019-2024 (K Units)
Figure 40. Middle East & Africa Long-acting Antipsychotic Revenue 2019-2024 ($ millions)
Figure 41. Americas Long-acting Antipsychotic Sales Market Share by Country in 2023
Figure 42. Americas Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Figure 43. Americas Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 44. Americas Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 45. United States Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 46. Canada Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 47. Mexico Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 48. Brazil Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 49. APAC Long-acting Antipsychotic Sales Market Share by Region in 2023
Figure 50. APAC Long-acting Antipsychotic Revenue Market Share by Region (2019-2024)
Figure 51. APAC Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 52. APAC Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 53. China Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 54. Japan Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 55. South Korea Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 56. Southeast Asia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 57. India Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 58. Australia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 59. China Taiwan Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 60. Europe Long-acting Antipsychotic Sales Market Share by Country in 2023
Figure 61. Europe Long-acting Antipsychotic Revenue Market Share by Country (2019-2024)
Figure 62. Europe Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 63. Europe Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 64. Germany Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 65. France Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 66. UK Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 67. Italy Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 68. Russia Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 69. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Country (2019-2024)
Figure 70. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Long-acting Antipsychotic Sales Market Share by Application (2019-2024)
Figure 72. Egypt Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 73. South Africa Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 74. Israel Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 75. Turkey Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 76. GCC Countries Long-acting Antipsychotic Revenue Growth 2019-2024 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Long-acting Antipsychotic in 2023
Figure 78. Manufacturing Process Analysis of Long-acting Antipsychotic
Figure 79. Industry Chain Structure of Long-acting Antipsychotic
Figure 80. Channels of Distribution
Figure 81. Global Long-acting Antipsychotic Sales Market Forecast by Region (2025-2030)
Figure 82. Global Long-acting Antipsychotic Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Long-acting Antipsychotic Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Long-acting Antipsychotic Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Long-acting Antipsychotic Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Long-acting Antipsychotic Revenue Market Share Forecast by Application (2025-2030)
